Skip to Content
Søg Menu

Update om behandling af myelomatose med bispecifikke antitoffer

Hør i denne MEDtalk om Agoston Gyula Szabos perspektivering af tre studier, præsenteret ved ASH 2021, omhandlende behandling af myelomatose med bispecifikt antistof.
Agoston Gyula Szabos

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Fredrik Schjesvold: Bridging Science and Clinical Innovation

/ Jan Andreasen
Myelomatose

Advancing Myeloma Research and Treatment: An Interview with Fredrik Schjesvold

/ Fredrik Schjesvold / Jan Andreasen
Myelomatose

Key Findings That Could Transform Multiple Myeloma Treatment

/ Jan Andreasen
ASH24Myelomatose
Fredrik Hellem Schjesvold

ASH 2024: Viktige funn som kan endre behandlingen av myelomatose

/ Fredrik Schjesvold
ASH24Myelomatose Play the Video 05:37
Muhammad Kashif

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Muhammad Kashif
AIASH24Myelomatose Play the Video 03:57
Meletios-Athanasios Dimopoulos

Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

/ Meletios A. Dimopoulos
ASH24Myelomatose Play the Video 03:38
Frida Bugge Askeland

Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma

/ Frida Bugge Askeland
ASH24Myelomatose Play the Video 03:10
Fredrik Schjesvold

ASH 2024 Highlights: Early Smouldering Myeloma Treatment and Breakthrough Therapies in Multiple Myeloma Take Center Stage

/ Fredrik Schjesvold
ASH24Myelomatose Play the Video 02:57
Alex Lesokhin

Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing Frequency in Refractory Multiple Myeloma

/ Alexander Lesokhin
ASH24Myelomatose Play the Video 4:45
Back to top